Source: yahoo_news
Source ID: yahoo:a77c2b12bbe6f5db1462c5b0788cb1bf:VNDA
URL: https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-provides-vqw-765-210000583.html?.tsrc=rss
Symbol: (VNDA)
Published: 2026-10-14 17:00:00 EDT
Time precision: minute
Title: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.